Efficacy and safety of subcutaneous interferon-β-1a in patients with a first demyelinating event and early multiple sclerosis

Bibliography

• Weinshenker BG, Bass B, Rice GP, et al. The natural history of multiple sclerosis: a geographically based study 1. Clinical course and disability. Brain 1989;112(Pt 1):133-46
   PubMed Web of Science ®Google Scholar
• Audoin B, Au Duong MV, Malikova I, et al. Functional magnetic resonance imaging and cognition at the very early stage of MS. J Neurol Sci 2006;245:87-91
   PubMed Web of Science ®Google Scholar
• Miller D, Barkhof F, Montalban X, et al. Clinically isolated syndromes suggestive of multiple sclerosis, part 1: natural history, pathogenesis, diagnosis, and prognosis. Lancet Neurol 2005;4:281-8
   PubMed Web of Science ®Google Scholar
• Calabrese M, Agosta F, Rinaldi F, et al. Cortical lesions and atrophy associated with cognitive impairment in relapsing-remitting multiple sclerosis. Arch Neurol 2009;66:1144-50
   PubMedGoogle Scholar
• Iannucci G, Tortorella C, Rovaris M, et al. Prognostic value of MR and magnetization transfer imaging findings in patients with clinically isolated syndromes suggestive of multiple sclerosis at presentation. AJNR Am J Neuroradiol 2000;21:1034-8
   PubMed Web of Science ®Google Scholar
• Ferguson B, Matyszak MK, Esiri MM, Perry VH. Axonal damage in acute multiple sclerosis lesions. Brain 1997;120:393-9
   PubMed Web of Science ®Google Scholar
• Comi G, Filippi M, Barkhof F, et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. Lancet 2001;357:1576-82
   PubMed Web of Science ®Google Scholar
• Jacobs LD, Beck RW, Simon JH, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating event in multiple sclerosis. CHAMPS Study Group. N Engl J Med 2000;343:898-904
   PubMed Web of Science ®Google Scholar
• Kappos L, Polman CH, Freedman MS, et al. Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242-9
   PubMed Web of Science ®Google Scholar
• Comi G, Martinelli V, Rodegher M, et al. Effect of glatiramer acetate on conversion to clinically definite multiple sclerosis in patients with clinically isolated syndrome (PreCISe study): a randomised, double-blind, placebo-controlled trial. Lancet 2009;374:1503-11
   PubMed Web of Science ®Google Scholar
• Scott LJ. Glatiramer acetate: a review of its use in patients with relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis. CNS Drugs 2013;27:971-88
   PubMed Web of Science ®Google Scholar
• Kieseier BC. The mechanism of action of interferon-beta in relapsing multiple sclerosis. CNS Drugs 2011;25:491-502
   PubMed Web of Science ®Google Scholar
• Poser CM, Paty DW, Scheinberg L, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983;13:227-31
   PubMed Web of Science ®Google Scholar
• McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the international panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-7
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”. Ann Neurol 2005;58:840-6
   PubMed Web of Science ®Google Scholar
• Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis. 2010 revisions to the “McDonald criteria”. Ann Neurol 2011;69:292-302
   PubMed Web of Science ®Google Scholar
• Brex PA, Ciccarelli O, O’Riordan JI, et al. A longitudinal study of abnormalities on MRI and disability from multiple sclerosis. N Engl J Med 2002;346:158-64
   PubMed Web of Science ®Google Scholar
• Freedman MS, Comi G, De Stefano N, et al. Moving toward earlier treatment of multiple sclerosis: findings from a decade of clinical trials and implications for clinical practice. Mult Scler Relat Disord 2014;3:147-55
   PubMed Web of Science ®Google Scholar
• Comi G, De Stefano N, Freedman MS, et al. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. Lancet Neurol 2012;11:33-41
   PubMed Web of Science ®Google Scholar
• Freedman MS, Comi G, De Stefano N, et al. Efficacy of two dosing frequencies of subcutaneous interferon beta-1a on the risk of conversion from a first demyelinating event to multiple sclerosis and on MRI measures of disease: 3-year results of Phase III, double-blind, multicentre trials (REFLEX and REFLEXION). Neurology 2012;78(Suppl):LB001.014
   Google Scholar
• De Stefano N, Comi G, Kappos L, et al. Effect of two dosing frequencies of subcutaneous interferon beta-1a on lesion volumes in patients with a first clinical demyelinating event suggestive of multiple sclerosis: results of the Phase III REFLEX study extension (REFLEXION). J Neurol 2012;259(Suppl 1):S110-11
   Google Scholar
• PRISMS Study Group. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-504
   PubMed Web of Science ®Google Scholar
• PRISMS Study Group, University of British Columbia MS/MRI Analysis Group. PRISMS-4: long-term efficacy of interferon-beta-1a in relapsing MS. Neurology 2001;56:1628-36
   PubMed Web of Science ®Google Scholar
• Kappos L, Traboulsee A, Constantinescu C, et al. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS. Neurology 2006;67:944-53
   PubMed Web of Science ®Google Scholar
• Lublin FD, Reingold SC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of new agents in multiple sclerosis. Neurology 1996;46:907-11
   PubMed Web of Science ®Google Scholar
• SPECTRIMS Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: clinical results. Neurology 2001;56:1496-504
   PubMed Web of Science ®Google Scholar
• The Once Weekly Interferon for MS Study Group. Evidence of interferon beta-1a dose response in relapsing-remitting MS: the OWIMS Study. Neurology 1999;53:679-86
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin DS, Francis G, et al. Randomized, comparative study of interferon beta-1a treatment regimens in MS: the EVIDENCE trial. Neurology 2002;59:1496-506
   PubMed Web of Science ®Google Scholar
• Panitch H, Goodin D, Francis G, et al. Benefits of high-dose, high-frequency interferon beta-1a in relapsing-remitting multiple sclerosis are sustained to 16 months: final comparative results of the EVIDENCE trial. J Neurol Sci 2005;239:67-74
   PubMed Web of Science ®Google Scholar
• Schwid SR, Thorpe J, Sharief M, et al. Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE study. Arch Neurol 2005;62:785-92
   PubMed Web of Science ®Google Scholar
• Trojano M, Pellegrini F, Paolicelli D, et al. Real-life impact of early interferon beta therapy in relapsing multiple sclerosis. Ann Neurol 2009;66:513-20
   PubMed Web of Science ®Google Scholar
• Kappos L, Freedman MS, Polman CH, et al. Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. Lancet Neurol 2009;8:987-97
   PubMed Web of Science ®Google Scholar